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Hypocalcemia is a known risk following bariatric surgery and can contribute to the development of osteoporosis. Osteoporosis is
commonly treated with denosumab, though denosumab can exacerbate underlying abnormalities in calcium homeostasis. We
present the case of a 59-year-old female with severe hypocalcemia who had been treated with denosumab for osteoporosis three
months before and had Billroth II gastric bypass surgery 15 years before, for bariatric purposes. Intravenous calcium supplementation was used to correct the initial electrolyte abnormality, and the patient was able to maintain appropriate calcium levels
on high doses of oral calcium before discharge. Denosumab-induced hypocalcemia has been previously reported in patients with
predisposing conditions including chronic kidney disease, primary sclerosing cholangitis, Crohn’s disease, and a history of sleeve
gastrectomy for marginal gastric ulcers. A few cases of hypocalcemia have been reported in patients with a history of bariatric
surgery secondary to vitamin D deﬁciency, but this report is unique in demonstrating denosumab-induced hypocalcemia after
bariatric surgery with normal vitamin D levels, suggesting a primary malabsorption of calcium. The risk of severe hypocalcemia
should be considered before initiating denosumab to treat osteoporosis in patients with a history of bariatric surgery. If
denosumab is initiated, serum calcium levels should be closely monitored, and patients should be educated about the importance
of adherence to calcium supplementation.

1. Introduction
With rising rates of obesity globally, bariatric surgery for
weight loss has become an increasingly safe and eﬀective
option for managing excess weight and associated metabolic
and mechanical complications [1, 2]. While bariatric surgical
procedures continue to be modiﬁed to maximize weight loss
while minimizing morbidity and mortality, they are not
without risk [1]. Suboptimal preoperative nutrition, anatomical changes, and postoperative dietary constraints can
lead to signiﬁcant micronutrient and vitamin deﬁciencies
after bariatric surgery, including hypocalcemia [2].
The combination of these nutritional deﬁciencies with
mechanical and hormonal changes resulting from bariatric
surgery can also contribute to the development of osteoporosis
[3]. Antiresorptive therapies such as bisphosphonates and

denosumab are ﬁrst-line treatments for osteoporosis, yet they
also pose a risk of hypocalcemia in predisposed patients,
ranging from minor and asymptomatic to life-threatening
conditions [4, 5]. Hypocalcemia is a known risk of both
bariatric surgical procedures and antiresorptive osteoporosis
therapies [2, 4, 6], but the hypocalcemia risk of these two
factors combined and the optimal treatment of those with
osteoporosis secondary to a history of bariatric surgery have
received little attention in the literature.
In this report, we present the case of a 59-year-old female
who developed severe hypocalcemia three months after
treatment with denosumab for osteoporosis and ﬁfteen years
after Billroth II gastric bypass surgery. This case was prepared in accordance with the CARE guidelines for case
reports (see Appendix 1 in Supplementary Materials for
CARE checklist).
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2. Case Presentation
A 59-year-old postmenopausal woman with a past medical
history of Billroth II gastric bypass surgery 15 years before
for bariatric purposes, Barrett esophagus, pericarditis secondary to suspected rheumatologic disease status treated
with a pericardial window 3 years before, rheumatoid arthritis with negative rheumatoid factor, paroxysmal atrial
ﬁbrillation, amiodarone-induced hypothyroidism, and osteoporosis treated with denosumab 3 months before was
referred to the emergency department by her endocrinologist after outpatient labs revealed profound hypocalcemia,
hypophosphatemia, and hypomagnesemia. The patient had
recently returned from vacation, where she experienced 2-3
episodes of diarrhea. She reported compliance to her
medications, which included 50,000 IU ergocalciferol daily
and 630 mg calcium citrate 2-3 times daily, apart from taking
a decreased dose of calcium for the last 4 days of her vacation
since she was running low on pills. She noted fatigue and
intermittent tingling in her hands, feet, and perioral region
for 2-3 days prior to admission. She denied weight loss, fever,
muscle cramping, seizures, loss of consciousness, or
lightheadedness.
On presentation, the patient was afebrile with a temperature of 98.2oF, blood pressure of 136/74 mmHg, heart
rate of 71 beats/min, and respiratory rate of 15 breaths/min.
Her oxygen saturation was 100% on room air. Physical
examination revealed a well-appearing woman with a body
mass index (BMI) of 30 kg/m2 in no acute distress. Neck was
supple with no thyromegaly. There were no abnormalities on
cardiac or pulmonary exam. Abdomen was soft, nontender,
and nondistended with normal bowel sounds. Patient had a
positive Chvostek’s sign. No muscle twitches or spasms were
appreciated. Strength, sensation, reﬂexes, and cranial nerves
were intact. The patient had no signs of confusion or
psychosis.
Blood tests from the emergency department revealed a
calcium of 5.8 mg/dL, phosphorus of <1 mg/dL, and magnesium of 1.7 mg/dL. Albumin was 3.8 g/dL, so the corrected
calcium was 6.0 mg/dL. Ionized calcium was 0.8 mg/dL.
Parathyroid hormone was 136 ng/L. 25-Hydroxy vitamin D
was normal at 46 ng/mL, and 1-25-hydroxy vitamin D was
normal at 30 pg/mL. Urinalysis was within normal limits,
and urine calcium was <2 mg/dL. Creatinine was 0.61 mg/
dL, and blood urea nitrogen was 11 mg/dL. TSH was normal
at 0.78 μU/mL. An electrocardiogram performed in the
emergency department showed normal sinus rhythm with a
corrected QT interval of 493 ms.
In the emergency department, the patient was given 2 g
of IV magnesium sulfate, 30 mmol of IV sodium phosphate,
and 1 g of IV calcium gluconate. During her 4-day hospital
stay, the patient continued to receive IV calcium, as well as
oral calcitriol, phosphate, and magnesium. When she was
able to consistently maintain serum calcium of at least
8.0 mg/dL on oral calcium citrate supplementation, she was
discharged with a calcium level of 8.0 mg/dL, magnesium of
1.9 mg/dL, and phosphorus of 2.3 mg/dL. She was instructed
to take calcium citrate of 1260 mg 4 times daily, calcitriol of
0.25 mcg 2 times daily, phosphorus of 250 mg 3 times daily,
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and magnesium oxide of 400 mg 2 times daily and to be
followed up closely with her endocrinologist. Since discharge, the patient has been able to maintain adequate
calcium levels on a low dose of calcium supplementation,
and she is interested in considering further doses of
denosumab.

3. Discussion
The risk of hypocalcemia following denosumab use for
osteoporosis has been demonstrated in multiple case reports
and case series for patients with chronic kidney disease
[7–10] and in individual case reports for patients with
primary sclerosing cholangitis [11], Crohn’s disease
[8, 12, 13], and a history of sleeve gastrectomy for marginal
gastric ulcers [12]. A few cases of hypocalcemia with
denosumab have been reported in patients with a history of
bariatric surgery, but each of these was likely secondary to
vitamin D deﬁciency [14, 15]. In our case, normal active and
storage forms of vitamin D, low phosphate, and normal
kidney function tests suggested that the hypocalcemia was
not due to renal failure or vitamin D deﬁciency. With these
etiologies excluded, the most likely cause of hypocalcemia
was primary calcium malabsorption from the bariatric
Billroth II procedure 15 years before, exacerbated by
denosumab use 3 months before and insuﬃcient calcium
supplementation during the week prior to admission.
Billroth II gastrectomy is a form of gastric bypass surgery
often used for refractory peptic ulcer disease and gastric
adenocarcinoma, but it can also be used for weight loss since
it reduces the volume of the stomach, causing early satiety
[16]. Due to a combination of anatomical changes, postoperative dietary changes, and suboptimal preoperative
nutrition, many patients develop micronutrient deﬁciencies
after bariatric surgery [2], and Billroth II procedure has been
shown to cause calcium and vitamin D absorption disturbances [17]. Because of the risk of hypocalcemia following
bariatric surgery, calcium supplementation and vitamin D
supplementation are recommended to prevent postoperative
hypocalcemia [14].
Even with adequate supplementation, the malabsorption
resulting from bariatric surgery, combined with mechanical
and hormonal factors related to weight loss, predisposes
patients to osteoporosis after bariatric surgery [3]. Denosumab, a common ﬁrst-line treatment for osteoporosis, is a
monoclonal antibody approved for prevention of skeletalrelated events in postmenopausal women at risk for osteoporosis (as Prolia ) and is given as a subcutaneous injection every six months [4, 18]. Denosumab functions by
inhibiting osteoclast-mediated bone resorption by binding
to the receptor activator of nuclear factor kappa B ligand
(RANKL), thus preventing RANKL from binding to its
receptor. As a result, less skeletal calcium is released into the
circulation [19]. Denosumab is known to exacerbate existing
hypocalcemia, so correction of preexisting hypocalcemia is
suggested prior to administration. Additionally, monitoring
of calcium, phosphorus, and magnesium is recommended,
and supplementation with at least 1000 mg daily of calcium
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and 400 IU of vitamin D is recommended, particularly
during the ﬁrst 14 days after administration [20].
Our patient experienced profound hypocalcemia 15
years after bariatric surgery and 3 months after denosumab
administration. Prior to this episode, the patient was on a
longstanding dose of 50,000 IU ergocalciferol daily, as well as
630 mg calcium citrate 2-3 times daily, which is well within
the recommendations of the Prolia insert [20]. She was
closely monitored by her rheumatologist and endocrinologist during the interval immediately after denosumab
administration, and she never experienced profound hypocalcemia during this time. Considering our patient had
two separate indications for calcium and vitamin D supplementation, perhaps she needed higher doses of oral
supplements, or she was particularly susceptible to a few
days of a decreased calcium dose while on vacation.
One previous study sought to identify risks for denosumab-induced hypocalcemia and found no signiﬁcant associations between clinical parameters and development of
hypocalcemia [5]. Notably, however, previous gastrointestinal surgeries were not included among the clinical parameters they assessed. The study concluded that high
baseline bone turnover, as evidenced by increased serum
bone turnover markers, was associated with denosumabinduced hypocalcemia [5]. Given that our patient likely had
a decreased ability to absorb calcium via the gastrointestinal
tract, it seems reasonable to hypothesize that she had high
baseline bone turnover.
Strengths of this case include the fact that the patient was
a reliable historian with a well-documented surgical and
medical history within the electronic medical record. Additionally, her established outpatient endocrinologist followed her in the hospital, allowing for continuity of care and
eﬀective outpatient follow-up. A weakness of the case is that
there is no way to parse out the relative contribution to
hypocalcemia of each potential factor—denosumab use,
chronic absorption issues from prior bariatric surgery, and
missed calcium supplementation and diarrhea in the days
leading up to admission. Additionally, given the timing of
the patient’s bariatric surgery relative to the current episode,
we do not have access to the degree of her weight loss after
the surgery; however, based on the history from the patient
and a current BMI of 30, we do not suspect that malabsorptive issues were a result of an overly aggressive
bariatric surgery. Further research is needed to determine
the risk of denosumab-induced hypocalcemia for various
bariatric surgical techniques, as well as to determine a safe
and cost-eﬀective way to select patients for extended calcium
monitoring after denosumab administration.
This case demonstrates that the risk of profound hypocalcemia should be weighed when considering initiation
of denosumab in a patient with a history of bariatric surgery.
While bariatric surgery has been shown to decrease bone
mineral density, a 2012 study in the British Medical Journal
showed that bariatric surgery does not have a signiﬁcant
eﬀect on fracture risk, at least over the short term [21]. So,
perhaps, treatment of osteoporosis secondary to bariatric
surgery can be less aggressive than treatment of primary
osteoporosis. For those patients with a bariatric surgery
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history who are started on denosumab for osteoporosis,
monitoring of calcium, phosphorus, and magnesium should
be extended beyond the 14-day interval recommended in the
Prolia insert, and higher doses of calcium, phosphorus,
magnesium, and vitamin D should be considered than those
recommended for general denosumab use. Finally, patients
should be educated about the importance of long-term
adherence to supplementation, as well as what symptoms
should prompt them to visit the emergency department.
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